Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events (fatal) compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in cardiac events (non fatal) compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) ‐ treated with an… compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEi) showed no clear difference in adverse events (episodes of peritonitis) ‐ not treated with an… compared with conventional therapy (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).
Angiotensin‐converting enzyme inhibitors (ACEIs) showed no clear difference in all‐cause mortality (RR) compared with placebo or no treatment (moderate certainty).
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in cardiovascular mortality (RR) Median compared with usual care (moderate certainty).
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in heart failure hospitalisation, first (RR) Range of compared with usual care (moderate certainty).
Angiotensin receptor neprilysin inhibitors (ARNIs) showed no clear difference in hyperkalaemia Range of compared with usual care (moderate certainty).
Angiotensin receptor neprilysin inhibitors (ARNIs) leads to lower all‐cause mortality (RR) Range of compared with usual care (high certainty).
Discontinuation by no treatment/placebo of antihypertensives showed no clear difference in all‐cause mortality compared with continuation (low certainty).
It is very uncertain whether discontinuation by no treatment/placebo of antihypertensives changes myocardial infarction (fatal and nonfatal) compared with continuation (very low certainty).
Discontinuation by no treatment/placebo of antihypertensives showed no clear difference in hospitalisation compared with continuation (low certainty).
Discontinuation by no treatment/placebo of antihypertensives showed no clear difference in stroke (fatal + nonfatal + TIA) compared with continuation (low certainty).